Steffen Wolfsgruber1,2, Alexandra Polcher1,2, Alexander Koppara1,2, Luca Kleineidam1,2, Lutz Frölich3, Oliver Peters4, Michael Hüll5, Eckart Rüther6, Jens Wiltfang6, Wolfgang Maier1,2, Johannes Kornhuber7, Piotr Lewczuk7,8, Frank Jessen2,9, Michael Wagner1,2. 1. Department of Psychiatry and Psychotherapy, University of Bonn, Germany. 2. German Center for Neurodegenerative Diseases, Bonn, Germany. 3. Department of Gerontopsychiatry, Central Institute of Mental Health, Mannheim, Germany. 4. Department of Psychiatry, Charité Berlin, Campus Benjamin Franklin, Berlin, Germany. 5. Center for Geriatric Medicine and Gerontology, University of Freiburg, Germany. 6. Department ofPsychiatry and Psychotherapy, University of Göttingen, Germany. 7. Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. 8. Department of Neurodegeneration Diagnostics, Medical University of Biasłystok, and Departmentof Biochemical Diagnostics, University Hospital of Bialystok, Bialystok, Poland. 9. Department of Psychiatry, University of Cologne, Germany.
Abstract
BACKGROUND: There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) and their predictive value for clinical progression in memory clinic patients with subjective cognitive decline (SCD). OBJECTIVE: To assess the frequency of abnormal CSF biomarkers of AD and their predictive value for clinical progression in memory clinic patients with SCD in comparison to patients with mild cognitive impairment (MCI) from the same cohort. METHODS: We analyzed prospective data from memory clinic patients of the German Competence Network Dementia cohort with a baseline diagnosis of SCD (n = 82) or MCI (n = 134), distinguished by actuarial neuropsychological MCI criteria ("Jak-Bondi criteria"). Risk of clinical progression during 3-year follow-up was evaluated with Cox-Proportional-Hazard models. RESULTS: Prevalence of abnormal values in CSF markers of tau-mediated neurodegeneration (67.8% versus 46.3%) but not of amyloid deposition (40.3% versus 35.4%) was significantly higher in MCI compared to SCD. The rate of incident AD dementia (26.1% versus 12.2%) was also significantly higher in MCI. In SCD, additional 22% progressed to MCI during follow-up. Combined amyloid/tau abnormality was the strongest predictor of clinical progression in both groups. CONCLUSION: High prevalence of biomarker abnormality and clinical progression, together with the predictive value of CSF biomarkers, in memory clinic patients with SCD support the validity and usefulness of this condition as a "pre-MCI" at risk stage of AD.
BACKGROUND: There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) and their predictive value for clinical progression in memory clinic patients with subjective cognitive decline (SCD). OBJECTIVE: To assess the frequency of abnormal CSF biomarkers of AD and their predictive value for clinical progression in memory clinic patients with SCD in comparison to patients with mild cognitive impairment (MCI) from the same cohort. METHODS: We analyzed prospective data from memory clinic patients of the German Competence Network Dementia cohort with a baseline diagnosis of SCD (n = 82) or MCI (n = 134), distinguished by actuarial neuropsychological MCI criteria ("Jak-Bondi criteria"). Risk of clinical progression during 3-year follow-up was evaluated with Cox-Proportional-Hazard models. RESULTS: Prevalence of abnormal values in CSF markers of tau-mediated neurodegeneration (67.8% versus 46.3%) but not of amyloid deposition (40.3% versus 35.4%) was significantly higher in MCI compared to SCD. The rate of incident AD dementia (26.1% versus 12.2%) was also significantly higher in MCI. In SCD, additional 22% progressed to MCI during follow-up. Combined amyloid/tau abnormality was the strongest predictor of clinical progression in both groups. CONCLUSION: High prevalence of biomarker abnormality and clinical progression, together with the predictive value of CSF biomarkers, in memory clinic patients with SCD support the validity and usefulness of this condition as a "pre-MCI" at risk stage of AD.
Authors: Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Jennifer L Thompson; David P Sheppard; Anastasia Matchanova; Erin E Morgan; Shayne Loft; Steven Paul Woods Journal: Neuropsychol Dev Cogn B Aging Neuropsychol Cogn Date: 2022-04-12
Authors: Frank Jessen; Rebecca E Amariglio; Rachel F Buckley; Wiesje M van der Flier; Ying Han; José Luis Molinuevo; Laura Rabin; Dorene M Rentz; Octavio Rodriguez-Gomez; Andrew J Saykin; Sietske A M Sikkes; Colette M Smart; Steffen Wolfsgruber; Michael Wagner Journal: Lancet Neurol Date: 2020-01-17 Impact factor: 44.182
Authors: Hanneke F M Rhodius-Meester; Hilkka Liedes; Juha Koikkalainen; Steffen Wolfsgruber; Nina Coll-Padros; Johannes Kornhuber; Oliver Peters; Frank Jessen; Luca Kleineidam; José Luis Molinuevo; Lorena Rami; Charlotte E Teunissen; Frederik Barkhof; Sietske A M Sikkes; Linda M P Wesselman; Rosalinde E R Slot; Sander C J Verfaillie; Philip Scheltens; Betty M Tijms; Jyrki Lötjönen; Wiesje M van der Flier Journal: Alzheimers Dement (Amst) Date: 2018-10-08
Authors: Ingrid S van Maurik; Rosalinde E R Slot; Sander C J Verfaillie; Marissa D Zwan; Femke H Bouwman; Niels D Prins; Charlotte E Teunissen; Philip Scheltens; Frederik Barkhof; Mike P Wattjes; Jose Luis Molinuevo; Lorena Rami; Steffen Wolfsgruber; Oliver Peters; Frank Jessen; Johannes Berkhof; Wiesje M van der Flier Journal: Alzheimers Res Ther Date: 2019-04-16 Impact factor: 6.982
Authors: Frank Jessen; Annika Spottke; Henning Boecker; Frederic Brosseron; Katharina Buerger; Cihan Catak; Klaus Fliessbach; Christiana Franke; Manuel Fuentes; Michael T Heneka; Daniel Janowitz; Ingo Kilimann; Christoph Laske; Felix Menne; Peter Nestor; Oliver Peters; Josef Priller; Verena Pross; Alfredo Ramirez; Anja Schneider; Oliver Speck; Eike Jakob Spruth; Stefan Teipel; Ruth Vukovich; Christine Westerteicher; Jens Wiltfang; Steffen Wolfsgruber; Michael Wagner; Emrah Düzel Journal: Alzheimers Res Ther Date: 2018-02-07 Impact factor: 6.982